Cellectis (ALCLS) Reports Financial Results For 3rd Quarter And First Nine Months 2016
11/23/2016 8:05:45 AM
NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced its results for the three-month period ended September 30, 2016 and for the nine-month period ended September 30, 2016.
comments powered by